The pregabalin market reached USD 1,794.5 million in 2024 and is projected to reach USD 2,631.16 million by 2032, growing at a CAGR of 4.9% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Pregabalin Market Size 2024
USD 1,794.5 million
Pregabalin Market, CAGR
4.9%
Pregabalin Market Size 2032
USD 2,631.16 million
The pregabalin market features strong competition among leading players such as Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Cipla Limited, Aurobindo Pharma Limited, Torrent Pharmaceuticals Ltd., and Intas Pharmaceuticals Ltd. These companies focus on large-scale generic manufacturing, pricing efficiency, and regulatory compliance to maintain competitiveness. North America leads the global pregabalin market with a market share of 38%, driven by high diagnosis rates of neuropathic pain, strong outpatient prescription volumes, and wide insurance coverage. Europe follows as a key region due to robust generic adoption and government-backed healthcare systems. Asia Pacific continues to gain importance, supported by expanding patient pools and improving access to affordable medications.
Pregabalin Market Insights
Rising prevalence of neuropathic pain, epilepsy, and fibromyalgia drives sustained demand, with neuropathic pain leading the indication segment with a 46% market share due to high prescription volumes and long-term therapy needs.
Strong generic penetration shapes market trends, as capsules dominate the dosage form segment with a 58% share, supported by physician preference, stable bioavailability, and large-scale generic manufacturing.
Intense competition exists among global and regional players, focusing on pricing efficiency, supply reliability, and distribution reach, with retail pharmacies leading distribution channels with a 52% market share.
North America leads regional demand with a 38% market share, followed by Europe at 29% and Asia Pacific at 22%, supported by chronic disease prevalence, generic adoption, and expanding healthcare access.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
The pregabalin market, by dosage form, includes capsules, tablets, and oral solutions. Capsules dominate this segment, holding a market share of 58%, driven by strong physician preference and established prescribing habits. Capsules offer accurate dosing, stable bioavailability, and ease of manufacturing, which supports large-scale generic production. Tablets account for a 27% share, supported by patient demand for easier swallowing and dose flexibility. Oral solutions represent a 15% share, mainly used in pediatric and geriatric populations. Growth in this segment is driven by rising chronic pain cases and steady availability of cost-effective generic capsule formulations.
For instance, Pfizer developed pregabalin capsules in strengths of 25 mg, 75 mg, 150 mg, and 300 mg, supporting flexible titration in chronic pain therapy.
By Indication
By indication, the pregabalin market covers neuropathic pain, epilepsy, fibromyalgia, and generalized anxiety disorder. Neuropathic pain leads the segment with a 46% market share, supported by high prescription volumes for diabetic neuropathy and postherpetic neuralgia. Strong clinical efficacy in nerve-related pain drives continued adoption. Epilepsy holds a 24% share, as pregabalin remains widely used as adjunctive therapy for partial-onset seizures. Fibromyalgia accounts for 18%, supported by long-term symptom management needs. Generalized anxiety disorder represents 12%, driven by off-label use and rising mental health awareness in select regions.
For instance, Lupin supplies pregabalin used alongside standard antiepileptic drugs in regimens involving twice-daily dosing schedules.
By Distribution Channel
The distribution channel segment includes hospital pharmacies, retail pharmacies, and online pharmacies. Retail pharmacies dominate with a 52% market share, supported by high outpatient prescription volumes and widespread geographic presence. Chronic therapy requirements encourage repeat purchases through retail outlets. Hospital pharmacies account for 31%, driven by inpatient treatment initiation and specialist prescribing in neurology departments. Online pharmacies hold a 17% share, supported by growing digital health adoption and home-delivery convenience. Expansion of e-prescriptions and chronic disease management programs continues to strengthen online channel growth, while retail pharmacies maintain leadership through accessibility and established patient trust.
Key Growth Drivers
Rising Burden of Neuropathic Pain and Epilepsy
The increasing prevalence of neuropathic pain and epilepsy remains a primary growth driver for the pregabalin market. Rising cases of diabetes, cancer-related nerve damage, and spinal disorders increase long-term pain management needs. Physicians continue to prescribe pregabalin due to its proven efficacy in nerve-related pain. Epilepsy treatment also supports steady demand, as pregabalin is widely used as adjunct therapy. Aging populations further raise diagnosis rates of chronic neurological disorders. Long-term treatment requirements promote repeat prescriptions, while improving access to neurological care in developing regions sustains volume growth.
For instance, Dr. Reddy’s Laboratories supplies pregabalin capsules, which are indicated as adjunctive therapy for adult patients with partial-onset seizures and are typically administered in divided doses throughout the day.
Strong Generic Drug Penetration
Expanding availability of generic pregabalin significantly supports market growth. Patent expirations enabled multiple manufacturers to introduce cost-effective alternatives across major regions. Lower pricing improved affordability and expanded patient access to therapy. Healthcare systems increasingly favor generics to control chronic treatment costs. High bioequivalence standards ensure clinical reliability, encouraging physician confidence. Increased competition also improves supply consistency across channels. These factors collectively drive volume-based growth and support widespread adoption in both retail and hospital pharmacies.
For instance, Aurobindo Pharma demonstrated bioequivalence to reference pregabalin within the required 80–125 pharmacokinetic range in crossover studies.
Expansion of Outpatient and Chronic Care Models
The shift toward outpatient treatment and chronic care management strengthens demand for pregabalin. Many neurological and pain-related conditions require long-term therapy outside hospital settings. Oral administration supports convenient home-based treatment. Early discharge policies increase outpatient prescription volumes. Chronic care programs focus on symptom control and relapse prevention, favoring stable medications. Telemedicine and digital follow-ups further support prescription continuity. These evolving care models reinforce pregabalin’s role in long-term disease management and sustain consistent market demand.
Key Trends & Opportunities
Growth of Online and Digital Pharmacy Channels
The rapid expansion of online pharmacies creates notable opportunities for the pregabalin market. Digital platforms improve access to chronic medications through home delivery and simplified refills. E-prescription systems enhance adherence and reduce treatment gaps. Patients managing long-term pain prefer convenient ordering options. Online channels also expand reach in semi-urban and underserved areas. Subscription-based delivery models support recurring demand. Regulatory clarity around digital healthcare strengthens consumer trust, positioning online pharmacies as a growing distribution avenue.
For instance, CVS Health processes digital prescription refills through its integrated e-pharmacy platforms and mobile applications, supporting continuous access to essential medications, including neurological drugs.
Increasing Off-Label Use in Anxiety Disorders
Rising off-label use of pregabalin for anxiety disorders presents a meaningful growth opportunity. Growing mental health awareness increases treatment demand across urban populations. Physicians prescribe pregabalin for generalized anxiety disorder due to rapid symptom relief. Patients intolerant to conventional antidepressants often prefer alternative therapies. Expanding psychiatric care access supports broader prescription use. Continued clinical evaluation may further validate expanded indications, supporting incremental demand beyond core neurological applications.
For instance, Teva supplies pregabalin in various strengths used for generalized anxiety disorder. Expanding psychiatric services support its clinical use.
Key Challenges
Safety Concerns and Regulatory Scrutiny
Safety concerns remain a critical challenge for the pregabalin market. Reported side effects such as dizziness, sedation, and dependence prompt cautious prescribing. Regulatory authorities closely monitor misuse potential in certain regions. Controlled substance classification in select markets restricts distribution. Physicians increasingly assess risk-benefit profiles for long-term therapy. Patient compliance issues also affect continuity of treatment. These factors may limit prescription growth and increase regulatory compliance costs for manufacturers.
Price Pressure and Intense Generic Competition
Strong pricing pressure poses another major challenge in the pregabalin market. High generic penetration results in aggressive price competition. Margin compression affects manufacturers, particularly smaller players. Public healthcare systems negotiate lower procurement prices, intensifying revenue pressure. Tender-based purchasing increases competition in hospital channels. Frequent price revisions impact financial stability. Manufacturers must focus on cost efficiency and scale to remain competitive in a highly commoditized market environment.
Regional Analysis
North America
North America holds a market share of 38% in the pregabalin market, supported by high diagnosis rates of neuropathic pain and epilepsy. Strong physician awareness and established treatment guidelines drive consistent prescribing. The presence of major generic manufacturers ensures stable drug availability and competitive pricing. Chronic pain management programs and outpatient care models support long-term therapy demand. High healthcare spending and insurance coverage improve patient access to prescription medications. Retail pharmacies dominate distribution, supported by repeat prescriptions. Regulatory oversight ensures product quality, sustaining physician confidence and reinforcing regional market leadership.
Europe
Europe accounts for a 29% market share in the pregabalin market, driven by widespread adoption of generic medicines. National healthcare systems actively promote cost-effective chronic therapies, supporting pregabalin usage. Rising prevalence of diabetic neuropathy and neurological disorders sustains prescription volumes. Hospital and retail pharmacies both contribute significantly to distribution. Strong regulatory frameworks ensure consistent product quality across countries. Aging populations increase long-term pain management needs. Expanded access to neurological care and standardized treatment protocols further support stable demand across Western and Central European markets.
Asia Pacific
Asia Pacific holds a market share of 22% in the pregabalin market, supported by large patient populations and improving healthcare access. Rising diabetes prevalence increases neuropathic pain cases across key countries. Expanding generic drug manufacturing improves affordability and supply stability. Growing awareness of neurological disorders drives higher diagnosis rates. Retail pharmacies play a key role in chronic medication access. Government initiatives to expand healthcare coverage support prescription growth. Rapid urbanization and improving clinical infrastructure continue to strengthen long-term demand across emerging and developed Asia Pacific markets.
Latin America
Latin America represents a 7% market share in the pregabalin market, supported by gradual improvements in healthcare access. Rising chronic pain and epilepsy diagnosis rates increase prescription demand. Generic drug adoption improves affordability in cost-sensitive healthcare systems. Public hospitals play a key role in treatment initiation, while retail pharmacies support long-term therapy. Government healthcare programs expand access to essential neurological medicines. Improving physician awareness and expanding urban healthcare infrastructure support steady growth, although pricing controls and budget constraints continue to influence regional market dynamics.
Middle East & Africa
The Middle East & Africa region accounts for a 4% market share in the pregabalin market, driven by expanding healthcare infrastructure in select countries. Rising awareness of chronic pain management supports prescription growth. Government investment in hospital development improves access to neurological treatments. Generic availability supports affordability across public healthcare systems. Hospital pharmacies dominate distribution due to centralized treatment models. Limited specialist availability in some areas restricts rapid expansion. However, gradual improvements in healthcare access and chronic disease management programs continue to support incremental market growth.
Pregabalin Market Segmentations:
By Dosage Form
Capsules
Tablets
Oral solutions
By Indication
Neuropathic pain
Epilepsy
Fibromyalgia
Generalized anxiety disorder
By Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Geography
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Competitive Landscape
Competitive landscape analysis in the pregabalin market highlights strong competition among key players including Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Cipla Limited, Aurobindo Pharma Limited, Torrent Pharmaceuticals Ltd., and Intas Pharmaceuticals Ltd. The market remains highly generic-driven, with companies competing on pricing, supply reliability, and regulatory compliance. Manufacturers focus on expanding production capacity and securing long-term contracts with hospital and retail pharmacy chains. Portfolio diversification and geographic expansion remain core strategies to offset pricing pressure. Strong distribution networks ensure consistent availability across regions. Companies also emphasize quality assurance and bioequivalence to maintain physician trust. Strategic partnerships with distributors and healthcare providers further strengthen market positioning and support sustained competitive presence.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In November 2025, Pfizer Inc. saw the Pfizer-branded pregabalin capsules fully replaced by the Lyrica brand in certain markets as Pfizer stock of the original product ran out.
In March 2023, Aurobindo Pharma Limited received final approval from the U.S. FDA for its pregabalin capsules (generic equivalent).
Report Coverage
The research report offers an in-depth analysis based on Dosage Form,Indication, Distribution Channeland Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
Demand for pregabalin will remain stable due to long-term neurological and pain management needs.
Generic dominance will continue to shape pricing and volume-based market growth.
Neuropathic pain treatment will remain the leading application across regions.
Outpatient and chronic care models will support consistent prescription volumes.
Retail pharmacies will maintain leadership in distribution due to accessibility and repeat demand.
Online pharmacy adoption will expand through e-prescription growth and home delivery services.
Asia Pacific will record faster volume growth driven by rising disease awareness.
Regulatory monitoring will influence prescribing practices and product positioning.
Manufacturers will focus on cost efficiency to manage competitive pricing pressure.
Strategic geographic expansion will support long-term market sustainability.
Table of Contents (The complete Toc, LoF and LoT are available in the sample report)
1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope 2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology 3. Executive Summary 4. Introduction
4.1. Overview
4.2. Key Industry Trends 5. Global Pregabalin Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast 6. Market Breakup by Dosage Form
6.1. Capsules
6.1.1. Market Trends
6.1.2. Market Forecast
6.1.3. Revenue Share
6.1.4. Revenue Growth Opportunity
6.2. Tablets
6.2.1. Market Trends
6.2.2. Market Forecast
6.2.3. Revenue Share
6.2.4. Revenue Growth Opportunity
6.3. Oral Solutions
6.3.1. Market Trends
6.3.2. Market Forecast
6.3.3. Revenue Share
6.3.4. Revenue Growth Opportunity 7. Market Breakup by Indication
7.1. Neuropathic Pain
7.1.1. Market Trends
7.1.2. Market Forecast
7.1.3. Revenue Share
7.1.4. Revenue Growth Opportunity
7.2. Epilepsy
7.2.1. Market Trends
7.2.2. Market Forecast
7.2.3. Revenue Share
7.2.4. Revenue Growth Opportunity
7.3. Fibromyalgia
7.3.1. Market Trends
7.3.2. Market Forecast
7.3.3. Revenue Share
7.3.4. Revenue Growth Opportunity
7.4. Generalized Anxiety Disorder
7.4.1. Market Trends
7.4.2. Market Forecast
7.4.3. Revenue Share
7.4.4. Revenue Growth Opportunity 8. Market Breakup by Distribution Channel
8.1. Hospital Pharmacies
8.1.1. Market Trends
8.1.2. Market Forecast
8.1.3. Revenue Share
8.1.4. Revenue Growth Opportunity
8.2. Retail Pharmacies
8.2.1. Market Trends
8.2.2. Market Forecast
8.2.3. Revenue Share
8.2.4. Revenue Growth Opportunity
8.3. Online Pharmacies
8.3.1. Market Trends
8.3.2. Market Forecast
8.3.3. Revenue Share
8.3.4. Revenue Growth Opportunity 9. Market Breakup by Region
9.1. North America
9.1.1. United States
9.1.1.1. Market Trends
9.1.1.2. Market Forecast
9.1.2. Canada
9.1.2.1. Market Trends
9.1.2.2. Market Forecast
9.2. Asia-Pacific
9.2.1. China
9.2.2. Japan
9.2.3. India
9.2.4. South Korea
9.2.5. Australia
9.2.6. Indonesia
9.2.7. Others
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. United Kingdom
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Others
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Others
9.5. Middle East and Africa
9.5.1. Market Trends
9.5.2. Market Breakup by Country
9.5.3. Market Forecast 10. SWOT Analysis
10.1. Overview
10.2. Strengths
10.3. Weaknesses
10.4. Opportunities
10.5. Threats 11. Value Chain Analysis 12. Porter’s Five Forces Analysis
12.1. Overview
12.2. Bargaining Power of Buyers
12.3. Bargaining Power of Suppliers
12.4. Degree of Competition
12.5. Threat of New Entrants
12.6. Threat of Substitutes 13. Price Analysis 14. Competitive Landscape
14.1. Market Structure
14.2. Key Players
14.3. Profiles of Key Players
14.3.1. Pfizer Inc.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. Financials
14.3.1.4. SWOT Analysis
14.3.2. Viatris Inc.
14.3.3. Teva Pharmaceutical Industries Ltd.
14.3.4. Sun Pharmaceutical Industries Ltd.
14.3.5. Dr. Reddy’s Laboratories Ltd.
14.3.6. Lupin Limited
14.3.7. Cipla Limited
14.3.8. Aurobindo Pharma Limited
14.3.9. Torrent Pharmaceuticals Ltd.
14.3.10. Intas Pharmaceuticals Ltd. 15. Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for Pregabalin market, and what is its projected size in 2032?
The pregabalin market was valued at USD 1,794.5 million in 2024 and is projected to reach USD 2,631.16 million by 2032.
At what Compound Annual Growth Rate is the Pregabalin market projected to grow between 2024 and 2032?
The pregabalin market is projected to grow at a CAGR of 4.9% during the forecast period from 2024 to 2032.
Which Pregabalin market segment held the largest share in 2024?
In the pregabalin market, the neuropathic pain indication segment held the largest share at 46% in 2024.
What are the primary factors fueling the growth of the Pregabalin market?
Growth of the pregabalin market is driven by rising neuropathic pain prevalence, strong generic penetration, and expansion of outpatient care models.
Who are the leading companies in the Pregabalin market?
Leading players in the pregabalin market include Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries Ltd.
Which region commanded the largest share of the Pregabalin market in 2024?
North America led the pregabalin market in 2024 with a market share of 38%, driven by strong prescription volumes.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The Pregnancy Medication market was valued at USD 42,234.5 million in 2024 and is expected to reach USD 124,770.3 million by 2032, expanding at a CAGR of 14.5% during the forecast period.
The Germany guidewires market was valued at USD 151 million in 2024 and is projected to reach USD 229.68 million by 2032, registering a CAGR of 5.4% during the forecast period.
Restrictive Cardiomyopathy Treatment market size was valued USD 105.8 million in 2024 and is expected to reach USD 166.1 million by 2032, expanding at a CAGR of 5.8% during the forecast period.
The Respiratory Syncytial Virus (RSV) Therapeutics market was valued at USD 1,542.48 million in 2024 and is projected to reach USD 4,493.54 million by 2032, expanding at a strong CAGR of 14.3% during the forecast period.
Substance Use Disorder Treatment Market size was valued USD 14200 million in 2024 and is anticipated to reach USD 30108.29 million by 2032, at a CAGR of 9.85% during the forecast period.
Vision Screeners Market size was valued USD 1189 million in 2024 and is anticipated to reach USD 2368.36 million by 2032, at a CAGR of 9% during the forecast period
Vitamin K market size was valued USD 2,448.6 Million in 2024 and is anticipated to reach USD 3,645.35 Million by 2032, at a CAGR of 5.1% during the forecast period.
The Occupational Health market size reached USD 5,106 million in 2024 and is projected to reach USD 8,324.15 million by 2032, growing at a CAGR of 6.3% during the forecast period.
The North America Medical Headgears market was valued at USD 9,340 million in 2024 and is expected to reach USD 13,487.13 million by 2032, growing at a CAGR of 4.7% during the forecast period.
The Ophthalmic Drugs market size was valued at USD 43,178 million in 2024 and is anticipated to reach USD 64,280.94 million by 2032, growing at a CAGR of 5.1% during the forecast period.
The Optic Nerve Disorders Treatment market size was valued at USD 3,816 million in 2024 and is anticipated to reach USD 5,680.44 million by 2032, growing at a CAGR of 5.1% during the forecast period.
The smart contact lens market was valued at USD 5,182.71 million in 2024 and is expected to reach USD 18,702.58 million by 2032, growing at a CAGR of 17.4% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$5999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
